The global cardiovascular anastomosis devices market size is expected to reach USD 2.54 billion by 2030. Additionally, the industry is projected to expand at a CAGR of 6.5% from 2022 to 2030. The prevalence of cardiovascular diseases is on the rise globally. They are one of the top three causes of death worldwide, being responsible for around 32% of the total global mortalities.
The adoption of anastomotic devices decreases the extent of aortic manipulation required for creating a graft based on aortic inflow. Hence, surgeons can safely construct aortocoronary grafts. Long-term graft patency is important in cardiovascular surgeries. Patient outcomes after cardiac surgeries are dependent on the quality of the anastomosis surgical techniques. These devices facilitate the anastomoses through minimal incisions.
Cardiac surgery patients were at an increased risk of COVID-19 during the pandemic; therefore, hospital admissions for elective procedures were reduced to prevent potential hospital-acquired infections. At the beginning of the pandemic, only emergency cardiovascular surgeries were allowed to operate, based on the surgical priority of the patient cases. As all the elective cardiac procedures were canceled, the overall market experienced a slowdown. According to the Society of Thoracic Surgeons Adult Cardiac Surgery, there was a significant reduction in adult cardiac surgeries.
The adoption of anastomotic devices decreases the extent of aortic manipulation required for creating a graft based on aortic inflow. Hence, surgeons can safely construct aortocoronary grafts. Long-term graft patency is important in cardiovascular surgeries. Patient outcomes after cardiac surgeries are dependent on the quality of the anastomosis surgical techniques. These devices facilitate the anastomoses through minimal incisions.
Cardiac surgery patients were at an increased risk of COVID-19 during the pandemic; therefore, hospital admissions for elective procedures were reduced to prevent potential hospital-acquired infections. At the beginning of the pandemic, only emergency cardiovascular surgeries were allowed to operate, based on the surgical priority of the patient cases. As all the elective cardiac procedures were canceled, the overall market experienced a slowdown. According to the Society of Thoracic Surgeons Adult Cardiac Surgery, there was a significant reduction in adult cardiac surgeries.
Cardiovascular Anastomosis Devices Market Report Highlights
- Based on product type, the manual anastomosis devices segment held a majority of the market share in terms of revenue in 2021, as they allow traditional hand-sewing running sutures and create a bloodless field around the aortic hole for anastomosis procedures.
- The automatic anastomosis devices segment is anticipated to showcase the fastest CAGR of 7.2% during the forecast period from 2022 to 2030, as they reduce aortic manipulation with minimal incisions and are used in critical surgical situations.
- Based on end-use, in 2021, the hospital segment held a majority of the market revenue share, as hospitals conduct the majority of the cardiovascular surgeries. The specialty clinics segment is expected to grow at the fastest CAGR of 7.9% during the forecast period.
- In 2021, North America dominated the market for cardiovascular anastomosis devices due to the rising prevalence of cardiovascular diseases in the region. Asia Pacific is anticipated to grow at the fastest rate during the forecast period, aided by the growing healthcare expenditure, improving treatment options, rising focus on R&D activities, and technological developments.
Table of Contents
Chapter 1. Report Scope and Objectives
Chapter 2. Methodology
Chapter 3. Executive Summary
Chapter 4. Market Variables, Trends & Scope
Chapter 5. Cardiovascular Anastomosis Devices Market: Product Type Analysis
Chapter 6. Cardiovascular Anastomosis Devices Market: End Use Analysis
Chapter 7. Cardiovascular Anastomosis Devices Market: Regional Analysis
Chapter 8. Competitive Analysis
Companies Mentioned
- Abbott Laboratories
- B. Braun Melsungen AG
- Getinge Ab
- Medtronic plc
- Peters Surgical
Methodology
LOADING...
